ASX:OCC

Orthocell (OCC) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
669,530 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
OCC stock logo

About Orthocell Stock (ASX:OCC)

Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia. The company offers CelGro, a naturally derived collagen medical device for use in multiple indications to augment the surgical repair of bone, peripheral nerves, tendons, and cartilage; and Ortho-ATI, a cell therapy for treatment of chronic tendon injuries. It also provides Ortho-ACI, an autologous chondrocyte implantation to treat articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental procedure; and Remplir, a collagen scaffold used in peripheral nerve repair. Orthocell Limited was incorporated in 2006 and is headquartered in Murdoch, Australia.

OCC Stock News Headlines

Orthocell moves closer to US market clearance and sales
Orthocell Ltd OCC
Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share
The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty.
Orthocell raising $3.5 million; adds heavy hitters to register
Orthocell on the cusp of significant growth
Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share
The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty.
Orthocell thrilled to welcome John Van Der Wielen as chairman
OCC.AX - Orthocell Limited
Orthocell’s Remplir™ added to Australian Prostheses list
See More Headlines
Receive OCC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Orthocell and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
317
Year Founded
N/A

Profitability

Net Income
$-7,420,000.00
Net Margins
-154.57%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$4.80 million
Book Value
A$0.01 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
0.09
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Paul Frederick Anderson (Age 58)
    CEO, MD & Executive Director
    Comp: $650.97k
  • Ms. Nicole Jane Telford
    Chief Financial Officer
  • Mr. Alex McHenry
    Chief Operating Officer
  • Prof. Ming Hao Zheng
    Chief Scientific Officer and Member of Medical & Scientific Advisory Board
  • Mr. Tony Macintyre
    Chief Manufacturing Officer
  • Mr. Peter Gordon Webse B.Bus (Age 61)
    FCIS, FCPA, FGIA, M.A.I.C.D., Company Secretary

OCC Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Orthocell own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Orthocell investors own include Plug Power (PLUG), Viralytics (VRACY), Genetic Technologies (GTG) and GP Strategies (GPX).

This page (ASX:OCC) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners